{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-022439","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.061479+00:00","generated_at":"2026-06-24T00:48:17.488172+00:00","sec_items":["1.01","5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Two Armistice Capital directors resign from Avalo board; CEO Garry Neil appointed Chairman","bullets":["Steven Boyd and Keith Maher resigned effective August 8, 2022, not due to any disagreement with the company.","Armistice Capital Master Fund irrevocably waived its right to appoint two directors to the board.","CEO Garry Neil replaces Boyd as Chairman; Dr. Magnus Persson remains Lead Independent Director.","Armistice's CIO expressed continued support for the company and its strategic progress."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-022439","json":"https://secwatch.observer/filing/0001628280-22-022439.json","markdown":"https://secwatch.observer/filing/0001628280-22-022439.md","text":"https://secwatch.observer/filing/0001628280-22-022439.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828022022439/0001628280-22-022439-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828022022439/avtx-20220808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:48:17.488172+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"277afcb7e6","claim":"Garry Neil was appointed as Chairman of the Board at Avalo Therapeutics, Inc..","evidence_excerpt":"The Board appointed the Company’s President and Chief Executive Officer and Board member, Dr. Garry Neil, M.D., to replace Mr. Boyd as Chairman of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828022022439/0001628280-22-022439-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"55138fefa7","claim":"Keith Maher resigned as Director at Avalo Therapeutics, Inc..","evidence_excerpt":"On August 8, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the investment manager to Armistice Capital Master Fund Ltd. (the “Master Fund”), notified the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) that they have resigned from their positions on the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828022022439/0001628280-22-022439-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9fcfb0468b","claim":"Steven Boyd resigned as Director at Avalo Therapeutics, Inc..","evidence_excerpt":"On August 8, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the investment manager to Armistice Capital Master Fund Ltd. (the “Master Fund”), notified the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) that they have resigned from their positions on the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828022022439/0001628280-22-022439-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}